The Pharmacy Times® Mental Health Resource Center is a comprehensive resource for clinical news and expert insights on conditions that affect mood, thinking, and behavior, including clinical depression, bipolar disorder, schizophrenia, anxiety, and post-traumatic stress disorder.
January 21st 2025
The study found that internalizing and externalizing factors, brain maturation, and decreasing volumes of brain regions were linked to eating disorders.
Exploring Therapeutic Advances for Bipolar Disorder With Mixed Features and Anxious Distress: An Update for Ph...
2.0 Credits / Neurology, Psychiatry
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
Prescription Digital Therapeutics in Schizophrenia: A Managed Care Perspective on Advancements
2.0 Credits / Psychiatry
View More
Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia
3.0 Credits / Psychiatry
View More
Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies
1.0 Credit / Psychiatry
View More
Mental Health First Aid, administered by the National Council for Behavioral Health, trains participants in mental health literacy, understanding risk factors and warning signs for mental health and addiction concerns and strategies for how to help someone in both crisis and non-crisis situations.
Read More
Bipolar Disorder: Opportunity for Pharmacists to Improve Adherence and Health Outcomes
As highly accessible health care professionals, pharmacists have the opportunity to improve medication adherence and health outcomes of patients with bipolar disorder.
Read More
Comparable Efficacy of Generic and Brand-Name Drugs for Chronic Conditions Shown in Study
March 26th 2019Although generic versions of prescription medications can be a cheaper alternative for patients, many perceive generics as less effective and less safe than their brand-name counterparts.
Read More
FDA OKs Esketamine Nasal Spray for Treatment-Resistant Depression
March 6th 2019Once Spravato is determined as an appropriate treatment option, in accordance with the REMS, the patient will be treated at a certified treatment center that is trained to administer the medicine and address patient needs.
Read More
FDA Updates Fluoroquinolone Labeling to Strengthen Mental Health, Hypoglycemia Risks
July 11th 2018Officials with the FDA are requiring safety label updates for fluoroquinolone antibiotics due to risks of mental health adverse effects and blood sugar disturbances, according to a press release
Read More